Sumitomo Pharma Co., Ltd.'s Form 4 filing

Myovant Sciences Ltd. (MYOV) · filed Sep 10, 2021

Accession no.: 0000899243-21-035564
Filed: Sep 10, 2021, 5:00 PM ET
Trade date: Sep 8-9, 2021
Filing delay: 2 days
Rule 10b5-1 plan: Not on the form (before 2023)

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market purchases total $1.51M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Sumitomo Pharma Co., Ltd.CIK 0001446601	10% Owner
Sumitovant Biopharma Ltd.CIK 0001798244	10% Owner
Sumitomo Chemical Co., Ltd.CIK 0001798550	10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Sep 8, 2021	Common Stock	PPurchaseAcquired	+21,902	$25.74^F2	+$563,663.3	49,317,180	Indirect
Sep 9, 2021	Common Stock	PPurchaseAcquired	+37,000	$25.52^F5	+$944,147.5	49,354,180	Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The transaction was executed in multiple trades ranging from $25.26 to $26.23 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

The transaction was executed in multiple trades ranging from $25.14 to $26.00 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)